Gene Therapy to Target CEA for Oncology is under clinical development by Chongqing Precision Biotech and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gene Therapy to Target CEA for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy to Target CEA for Oncology overview

Gene-modified cell therapy is under development for the treatment of relapsed and refractory CEA positive malignant tumors, metastatic colorectal cancer, esophageal cancer, gastric cancer, and metastatic pancreatic cancer. It is administered through intravenous route. The drug candidate comprises T cells modified to express chimeric antigen receptors (CART) acts by targeting carcinoembryonic antigen-expressing (CEA) tumors.

For a complete picture of Gene Therapy to Target CEA for Oncology’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.